2225 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for multifactorial diseases Animal model for cardiovascular diseases
METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION
#2GENETICALLY MODIFIED MOUSE, METHODS FOR PRODUCING THE SAME, AND USES THEREOF
#3DOMINANT ACTIVE YAP, A HIPPO EFFECTOR, INDUCES CHROMATIN ACCESSIBILITY AND CARDIOMYOCYTE RENEWAL
#4TREATMENT METHOD OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING AN ACUTE MYOCARDIAL INFARCTION
#5Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids
#6METHOD FOR THE DIAGNOSIS AND TREATMENT OF ESSENTIAL PRIMARY HYPERTENSION
#7TREATMENT OF EXCESSIVE NEOVASCULARIZATION
#8Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal
#9TGFbeta1 Hyperactivation Causes Gender-Specific Calcific Aortic Stenosis
#10GENETIC MODIFICATION NON-HUMAN ORGANISM, EGG CELLS, FERTILIZED EGGS, AND METHOD FOR MODIFYING TARGET GENES
#11USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS
#12Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
#13Reelin antibodies for treatment of atherosclerosis
#14Method for treating or preventing heart failure
#15MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF
#16A METHOD FOR REGULATING THE FUNCTION OF A HEART CELL, RELATED NUCLEOTIDES AND COMPOUNDS
#17Method for Treating Ischemic Tissue
#18MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS
#19Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same
#20Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal
#21Medical use of CREG protein
#22GENETIC MODIFICATION NON-HUMAN ORGANISM, EGG CELLS, FERTILIZED EGGS, AND METHOD FOR MODIFYING TARGET GENES
#23Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells
#24NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENE
#25Compositions and methods for genetically modifying myosin phosphatase target subunit (Mypt1) gene for lowering blood pressure
#26PROTOCOL FOR INCREASING LIFE EXPECTANCY IN A TEST SUBJECT
#27TREATMENT OF EXCESSIVE NEOVASCULARIZATION
#28Antibodies to oxidized phospholipids
#29Antibodies to oxidized phospholipids
#30Modulating phosphatase activity in cardiac cells
#31Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
#32METHOD FOR PREPARING A CANINE MODEL OF ATHEROSCLEROSIS
#33Methods and compositions for treatment of atherosclerosis
#34Antibodies to oxidized phospholipids
#35COMPOSITIONS AND METHODS FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS
#36Micro-RNA family that modulates extracellular matrix genes and uses thereof
#37Transgenic animal for visualization of ATP and use thereof
#38Disease model pig exhibiting stable phenotype, and production method thereof
#39ANIMAL MODELS FOR CARDIOMYOPATHY
#40Method for sorting cardiomyocytes
#41Non-human animals having an engineered ANGPTL8 gene
#42MicroRNA induction of cardiac regeneration
#43Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
#44Cell and gene based methods to improve cardiac function
#45Micro-RNA family that modulates fibrosis and uses thereof
#46Micro-RNA family that modulates fibrosis and uses thereof
#47Micro-RNA family that modulates fibrosis and uses thereof
#48Role of a cluster of long noncoding RNA transcripts in protecting the heart from pathological hypertrophy
#49ANIMAL MODEL FOR EVALUATING PERFORMANCE OF HEMOSTATIC AGENT FOR INDUCING HEMORRHAGE IN COMMON CAROTID ARTERY OR SUPERIOR SAGITTAL SINUS, AND USE THEREOF
#50Regeneration of coronary artery by coronary endothelial specific progenitor cells
#51Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor
#52Extracellular vesicles derived from Gram-positive bacteria, and use thereof
#53Mitochondrial-nuclear exchanged cells, tissues, organs and animals
#54TRANSGENIC MOUSE EXPRESSING HUMAN LIPOPROTEIN (A) WITH DISABLED VITAMIN C GENE AND ITS USE AS A DISEASE TREATMENT MODEL
#55Model and method for a transgenic bovidae expressing cardiac fibrosis and associated pathology
#56Nonhuman mammal whose mtDNA is from a nonhuman mammal resistant to a selected disease or disorder and whose nDNA is from a nonhuman donor mammal more susceptible to the selected disease or disorder
#57Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair
#58Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
#59ANF-RGC in-gene knock-out animal
#60Micro-RNA family that modulates fibrosis and uses thereof
#61Micro-RNA family that modulates fibrosis and uses thereof
#62Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor
#63Micro-RNA family that modulates fibrosis and uses thereof
#64METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
#65Compositions and methods for preparing recombinant MG53 and methods for optimizing same
#66MOUSE MODEL FOR AVM
#67NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
#68METHODS OF IMPROVING CARDIAC FUNCTION AND ATTENUATING AND/OR PREVENTING CARDIAC REMODELING WITH HSP20
#69COMPOSITIONS RELATING TO A PHOSPHOPROTEIN AND METHODS OF USE
#70PNMT as a novel marker for progenitor cells
#71Upregulation of integrin linked kinase (ILK) to provide cardioprotective effects
#72Extracellular vesicles derived from gram-positive bacteria, and use thereof
#73Method for preventing and treating cardiovascular diseases with BRCA1
#74Selective infarcted-tissue-targeting bacteria and use thereof
#75NON-HUMAN ANIMAL MODEL OF MYOCARDIAL INFARCTION AND METHOD FOR CREATING THE SAME
#76Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
#77COMPOSITIONS AND METHODS FOR DETECTING, TREATING, OR PREVENTING REDUCTIVE STRESS
#78NOVEL USES OF VEGFXXXB
#79Targets for treatment of hypercholesterolemia
#80CALCIUM SENSOR STIM1 AND THE PLATELET SOC CHANNEL ORAI1 (CRACM1) ARE ESSENTIAL FOR PATHOLOGICAL THROMBUS FORMATION
#81MG53 COMPOSITIONS AND METHODS OF USE
#82MG53 COMPOSITIONS AND METHODS OF USE
#83MODULATING ANGIOGENESIS
#84Erk1/2 posphorylation site specific antibody
#85G-Protein Coupled Receptor 30 (GPR30) transgenic animals as a model for cardiovascular diseases
#86ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR
#87Gene disruptions, compositions and methods relating thereto
#88SULFONYLUREA RECEPTOR AND MEANS FOR TREATING ISCHAEMIA
#89Animal model for cigarette-smoke-induced atherosclerosis and related methods
#90USE OF P27KIP1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
#91Transgenic mouse comprising a disrupted Fibulin-4 gene as a model for cardiovascular disease
#92MODULATION OF THE INTEGRIN LINKED KINASE SIGNALING PATHWAY TO PROMOTE CARDIAC CELL PROLIFERATION AND SELF-RENEWAL
#93E-selectin compositions and use thereof for inducing E-selectin tolerance
#94METHODS FOR IDENTIFICATION AND SELECTION OF HUMAN EMBRYONIC STEM CELL DERIVED CELLS
#95Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
#96GENOMIC EDITING OF GENES INVOLVED IN CARDIOVASCULAR DISEASE
#97METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
#98Methods for inhibiting angiogenesis using EGFL8 antagonists
#99REGULATION OF CARDIAC CONTRACTILITY AND HEART FAILURE PROPENSITY
#100METHODS FOR PRODUCTION OF ATRIAL PROGENITORS AND THEIR DIFFERENTIATION INTO SMOOTH MUSCLE CELLS AND CARDIOMYOCYTES
#101Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
#102DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS
#103Prophylactic or therapeutic agent for diabetic maculopathy
#104Cardiac Conduction System (CCS) Progenitor Cells and Uses Thereof
#105Micro-RNA family that modulates fibrosis and uses thereof
#106METHODS, COMPOSITIONS AND TRANSGENIC MODELS RELATED TO THE INTERACTION OF T-CADHERIN AND ADIPONECTIN
#107Methods of identifying small molecules for renewals, survival and migration of cardiac progenitors
#108Methods for producing a non human model for aortic aneurysm
#109Method for increasing cardiac mass and performance
#110Remedy for the treatment of cardio-vascular diseases or disorders
#111Methods for increasing vascular density and maintaining viability of microvascular endothelial cells using trk receptor ligands
#112COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASES
#113SELECTIVE INHIBITION OF HISTONE DEACETYLASES 1 AND 2 AS A TREATMENT FOR CARDIAC HYPERTROPHY
#114METHODS AND COMPOSITIONS TO TREAT ARRHYTHMIAS
#115METHODS OF GENERATING CARDIOMYOCYTES
#116Methods for treating hypercholesterolemia
#117IDENTIFICATION OF GROUP OF HYPERTENSION-SUSCEPTIBILITY GENES
#118ANIMAL MODEL FOR THE SELECTION AND VALIDATION OF AGENTS ACTIVE AGAINST PULMONARY EMPHYSEMA AND COLORECTAL CANCER
#119Artery- and vein-specific proteins and uses therefor
#120Large Animal Model for Human-Like Advanced Atherosclerotic Plaque
#121Treatment of excessive neovascularization
#122Method for preventing and treating cardiovascular diseases with BRCA1
#123Animal model exhibiting cancer, pulmonary emphysema and cardiomyopathy
#124METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
#125Cardiac hypertrophy
#126Stably transformed bone marrow-derived cells and uses thereof
#127Transgenic animal and methods for decreasing cardiac cell death via cardiac-specific sir2alpha overexpression
#128Compositions and Methods for Modulating Osteoblast Cell Differentiation and Bone Generation Through HIF-1a
#129MITOCHONDRIAL-NUCLEAR EXCHANGED CELLS, TISSUES, ORGANS AND ANIMALS
#130MG53 compositions and methods of use
#131SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES
#132MODULATING ANGIOGENESIS
#133Novel Gene Disruptions, Compositions and Methods Relating Thereto
#134Animal Model With Induced Arrhythmia
#135Polymorphisms and Haplotypes of the Alpha 2C Adrenergic Receptor Gene
#136COMPOSITION AND METHOD FOR CLUSTERIN-MEDIATED STEM CELL THERAPY FOR TREATMENT OF ATHEROSCLEROSIS AND HEART FAILURE
#137Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling
#138Identification of a micro-RNA that activates expression of β-myosin heavy chain
#139BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
#140Muscle lamin A/C interacting protein, gene encoding same, and uses therefor
#141p300 transgenic animal
#142PNMT as a novel marker for progenitor cells
#143Angiogenesis Affecting Polypeptides, Proteins, and Composition, and Methods of Use Thereof
#144Methods and compositions related to mutant Kunitz domain I of TFPI-2
#145TRANSGENIC TIEG NON-HUMAN ANIMALS
#146Construction of Arterial Occlusive Disease Animal Model
#147Methods for treating vascular disease
#148Chimeric proteins with phosphatidylserine binding domains
#149Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
#150Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation
#151Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
#152Compositions and methods for regulating cardiac performance
#153Animal Model for Studying Atherosclerotic Lesions
#154Treatment and prevention of vascular dementia
#155COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS
#156METHODS OF INDUCING AND TREATING VASCULAR DISEASE
#157Inhibitor of cardiac tachyarrhythmias
#158Composition For Screening Anti-Hypertension Drug Comprising Mammal Tctp Gene or Its Protein Product, and Method For Screening Anti-Hypertension Drug Using Said Composition
#159Modulating phosphatase activity in cardiac cells
#160Gene disruptions, compositions and methods relating thereto
#161Methods of identifying small molecules for renewal, survival and migration of cardiac progenitors
#162Mouse model of chronic heart failure and coronary atherosclerosis regression
#163Method Of Constructing Animal Model Suffereing From Left Ventricular Diastolic Disorder For Examining Heart Failure And Method Of Examining Remedy For Heart Failure Caused By Left Ventricular Diastolic Failure With The Use Of The Animal Model
#164Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death
#165Prophylactic or therapeutic agent for diabetic maculopathy
#166Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascualr disorders
#167Methods And Compositions Using Adiponectin For Treatment Of Cardiac Disorders And For Stimulation Of Angiogenesis
#168Methods for treating conditions associated with MASP-2 dependent complement activation
#169Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby
#170Methods for increasing capillary density and maintaining viability of microvascular cardiac endothelial cells using trk receptor ligands
#171Transgenic amphibian models for lymphatic vessel development
#172Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
#173Transgenic animal and methods for decreasing cardiac cell death via cardiac-specific SIR2alpha overexpression
#174Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with Hsp20
#175Uses for Eph receptor antagonists and agonists
#176Endothelial cell specific antibodies and uses thereof
#177Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
#178Artery-and vein-specific proteins and uses therefor
#179Transgenic animal having fatty acid desaturase and method of producing the same
#180Animal models of long QT syndrome and uses thereof
#181Chimeric proteins with phosphatidylserine binding domains
#182Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
#183Mouse cardiac conduction system model
#184GNG4 gene disruptions, compositions and methods related thereto
#185Methods for preventing or treating a condition or a disease associated with angiogenesis
#186Selective inhibition of rock1 in cardiac therapy
#187Protein tyrosine phosphatase RPTP-beta disruptions, compositions and methods relating thereto
#188Transgenic mice containing beta3GalT2 gene disruptions
#189Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site
#190Transgenic mice containing CLCN4 chloride ion channel gene disruptions
#191Adiponectin-knoucout nonhuman animal
#192Melusin a muscle specific protein, as a drug target for prevention and treatment of heart failure
#193Transgenic TIEG non-human animals
#194Artery- and vein-specific proteins and uses therefor
#195Zebrafish assay
#196Method for producing heart-specific fluorescence of non-human eukaryotic animals
#197Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death
#198BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
#199Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
#200Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells and uses thereof
#201Inducible heart attack animal model
#202Artery- and vein-specific proteins and uses therefor
#203Knockin non-human animal and tissue-specific MnSOD knockout non-human animal
#204Methods and cell populations for identifying and validating genomic targets, and for drug screening
#205Expressed ligand-vascular intercellular signaling molecule
#206CCN1 transgenic animals
#207Desmin gene having novel point mutation causative of dilated cardiomyopathy
#208Method of screening a midkine modulating agent
#209Transgenic zebrafish models for thrombosis
#210Compositions and methods for the treatment and diagnosis of immune disorders
#211Expressed ligand-vascular intercellular signaling molecule
#212Inhibitor of cardiac tachyarrhythmias
#213Regulation of cardiac contractility and heart failure propensity